Brian Cheng
Stock Analyst at JP Morgan
(2.26)
# 2,754
Out of 5,072 analysts
73
Total ratings
48.28%
Success rate
-4.38%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OPK OPKO Health | Initiates: Neutral | n/a | $1.35 | - | 1 | Nov 20, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $68 → $81 | $89.86 | -9.86% | 6 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Underweight | $12 → $5 | $8.55 | -41.52% | 5 | Nov 7, 2025 | |
| XNCR Xencor | Maintains: Overweight | $20 → $18 | $17.26 | +4.29% | 5 | Nov 6, 2025 | |
| RVMD Revolution Medicines | Maintains: Overweight | $71 → $82 | $76.32 | +7.44% | 1 | Nov 6, 2025 | |
| ZYME Zymeworks | Maintains: Overweight | $20 → $23 | $26.18 | -12.15% | 3 | Oct 16, 2025 | |
| ALLO Allogene Therapeutics | Downgrades: Underweight | n/a | $1.36 | - | 5 | Oct 10, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Underweight | n/a | $1.56 | - | 1 | Oct 10, 2025 | |
| ABSI Absci | Initiates: Overweight | n/a | $3.07 | - | 1 | Oct 2, 2025 | |
| IMVT Immunovant | Maintains: Overweight | $37 → $33 | $23.95 | +37.79% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $47 | $45.51 | +3.27% | 2 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $20.86 | -4.12% | 7 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $53.57 | +30.67% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.67 | - | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $18.30 | +20.22% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $32.37 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.39 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $7.39 | +346.55% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.67 | +259.28% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $125 | $27.41 | +356.12% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.83 | +1,596.15% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.39 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.60 | +900.17% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.08 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.27 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $6.80 | +1,150.00% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $6.85 | +206.57% | 1 | Aug 3, 2021 |
OPKO Health
Nov 20, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Protagonist Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $68 → $81
Current: $89.86
Upside: -9.86%
Intellia Therapeutics
Nov 7, 2025
Downgrades: Underweight
Price Target: $12 → $5
Current: $8.55
Upside: -41.52%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $20 → $18
Current: $17.26
Upside: +4.29%
Revolution Medicines
Nov 6, 2025
Maintains: Overweight
Price Target: $71 → $82
Current: $76.32
Upside: +7.44%
Zymeworks
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $26.18
Upside: -12.15%
Allogene Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.36
Upside: -
Pliant Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.56
Upside: -
Absci
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.07
Upside: -
Immunovant
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $23.95
Upside: +37.79%
Sep 26, 2025
Maintains: Overweight
Price Target: $41 → $47
Current: $45.51
Upside: +3.27%
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $20.86
Upside: -4.12%
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $53.57
Upside: +30.67%
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $3.67
Upside: -
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $18.30
Upside: +20.22%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $32.37
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.39
Upside: -
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $7.39
Upside: +346.55%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.67
Upside: +259.28%
Mar 19, 2024
Upgrades: Neutral
Price Target: $125
Current: $27.41
Upside: +356.12%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.83
Upside: +1,596.15%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $4.39
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.60
Upside: +900.17%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.08
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $3.27
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $6.80
Upside: +1,150.00%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $6.85
Upside: +206.57%